BMS-316810

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: BMS-316810
• 英文别名: N-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-N-(thiophen-3-ylmethyl)pyridine-2-sulfonamide
• 化学式: C₂₅H₂₄N₆O₂S₂
• 分子量: 504.637
• InChiKey: FPEPZFNRGIPRRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  吡啶-2-磺酰氯 在 三乙基硅烷 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 BMS-316810
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

  摘要：

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.004

文献信息

• HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20110009387A1

  公开（公告）日：2011-01-13

  The present invention relates e.g., to methods for predicting cellular sensitivity to farnesyl protein transferase inhibitors, such as lonafarnib; manumycin A; FTI-276; L-744832; BMS-214662; tipifarnib; BMS-316810K. The methods involve determining if malignant cells exhibit increased expression. of phosphorylated histone H2Ax following contact of one or more of said cells with said inhibitor.

  本发明涉及例如，用于预测细胞对法尼酰蛋白转移酶抑制剂（如洛纳法尼布、马努霉素A、FTI-276、L-744832、BMS-214662、替匹法尼布、BMS-316810K）的敏感性的方法。该方法涉及确定恶性细胞是否在与该抑制剂中的一个或多个细胞接触后表现出磷酸化组蛋白H2Ax的表达增加。
• PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY
  申请人：Levitan Diane

  公开号：US20080090242A1

  公开（公告）日：2008-04-17

  The present invention provides, inter alia, methods for selecting a patient with cancer for treatment with a farnesyl protein transferase inhibitor as well as methods for treating said patient.
• [EN] HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY<br/>[FR] BIOMARQUEUR DE L'HISTONE H2AX (HH2AX) POUR UNE SENSIBILITÉ À FTI
  申请人：SCHERING CORP

  公开号：WO2008156613A1

  公开（公告）日：2008-12-24

  [EN] The.present invention relates e.g., to methods for predicting cellular sensitivity to farnesyl protein transferase inhibitors, such as lonafarnib; manumycin A; FTI-276; L-744832; BMS-214662; tipifarnib; BMS-316810K. The methods involve determining if malignant cells exhibit increased expression. of phosphorylated histone H2Ax following contact of one or more of said cells with said inhibitor.
  [FR] La présente invention porte par exemple sur des procédés pour prédire une sensibilité cellulaire aux inhibiteurs de la farnésyl protéine transférase, tels que le lonafarnib; la manumycine A; FTI-276; L-744832; BMS-214662; le tipifarnib; BMS-316810K. Les procédés mettent en jeu la détermination du fait de savoir si des cellules malignes présentent une expression accrue de l'histone phosphorylée H2Ax suivant le contact d'une ou de plusieurs desdites cellules avec ledit inhibiteur.
• Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors
  作者：Louis J. Lombardo、Amy Camuso、John Clark、Krista Fager、Johnni Gullo-Brown、John T. Hunt、Ivan Inigo、David Kan、Barry Koplowitz、Francis Lee、Kelly McGlinchey、Ligang Qian、Carolyn Ricca、George Rovnyak、Sarah Traeger、John Tokarski、David K. Williams、Laurence I. Wu、Yufen Zhao、Veeraswamy Manne、Rajeev S. Bhide

  DOI：10.1016/j.bmcl.2005.02.004

  日期：2005.4

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.